Boehringer Ingelheim

Genetically engineered antibodies are deployed successfully in cancer diagnostics and therapy. Therapeutic antibodies against Alzheimer’s disease and multiple sclerosis are currently under development. An important criterion when designing suitable antibody fragments is their stability. Comparing the antibodies of sharks, which … Read the full press release →

For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4 Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4 The analysed … Read the full press release →

Ground-breaking ceremony for leading veterinary manufacturing plant in Taizhou/China Investment of 58 million Euro 200 job opportunities expected Taizhou, Jiangsu, China, and Ingelheim, Germany, 27-8-2013 — /EuropaWire/ — Today, the research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical … Read the full press release →

Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis The milestone coincides with … Read the full press release →

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release →

Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of $83.4 million; adjusted diluted EPS of $0.27 per shareNew program authorized to repurchase up to $100 million in QIAGEN shares … Read the full press release →

2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release →

Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release →

14-1-2013 — /europawire.eu/ — Gezielte Förderung von Wachstumsunternehmen belebt Wirtschaft und wertet Standort Österreich auf – 44 junge Firmen in der Gründungsphase mit 16,5 Millionen Euro unterstützt. Technologieorientierte Start-Ups wurden im Vorjahr aus Mitteln des Wirtschaftsministeriums stärker denn je zuvor bei … Read the full press release →

Announces it will begin remainder of pre-planned clinical trials for LY2605541 INDIANAPOLIS, IN, USA, and INGELHEIM, GERMANY, 11-1-2013 — /europawire.eu/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim International GmbH announced today they will adjust the scope of their … Read the full press release →

CVMP opinions on veterinary medicinal products  14-12-2012 — /europawire.eu/ — The Committee adopted by consensus a positive opinion for an initial marketing authorisation application for: Semintra (telmisartan), from Boehringer Ingelheim Vetmedica GmbH, for chronic kidney disease in cats. The Committee adopted … Read the full press release →

5-12-2012 — /europawire.eu/ — In a study in mice, scientists at Karolinska Institutet in Sweden have discovered a new potential therapy that may reduce brain damage following stroke in type 2 diabetic patients. The suggested drug is already approved for the … Read the full press release →